Skip to main content
SpringerLink
Log in

Impurity Profiling of a Novel β-Lactam Enhancer: Zidebactam

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

A Correction to this article was published on 08 March 2022

This article has been updated

Abstract

Zidebactam (ZID) is a novel drug in clinical development; it potentiates the antibacterial activity of β-lactam antibiotics. Two reversed phase liquid chromatographic (RP-LC) methods were developed for ZID; a mass spectrometer (MS) compatible method for identification and another UV detection method for the quantification of impurities. Four impurities and three degradation products (DPs) were identified using LC–MS/MS. Both methods were developed on Hydrosphere C18 stationary phase which was found to be unique for the purpose due to its hydrophilic surface. The chromatographic separation of ZID and impurities was achieved in gradient mode using mobile phase consisting of ammonium formate in LC–MS/MS studies and ammonium dihydrogen phosphate in UV method. Acetonitrile (ACN) was employed as an organic solvent. ZID was subjected to hydrolytic, oxidative, photolytic and thermal stress conditions. The degradation was observed in acidic, basic and oxidative conditions. The UV method was validated. The method was accurate and precise to quantify impurities; accuracy was greater than 99.8% with precision of less than 4%. The method was highly sensitive to detect impurities as low as 1.4 ng on column. The developed method was employed for quality control and stability studies of the new drug substance during pre-clinical and clinical studies. The same method was also adapted for analysis of a parenteral drug product.

Graphic abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Change history

References

  1. Joshi SN, Wankhede KS, Jadhav SB, Pawar SS, Ahirrao VK, Bhawsar SB, Deshpande PK, Yeole RD, Patel MV (2013) A process for preparation of (2S,5R)-7-Oxo-6-sulphooxy-2-[Nʹ-((3R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza- bicyclo[3.2.1]octane. World Intellectual Property Organization: International application published under the patent cooperation treaty (PCT), Publication Number WO2014/135931

  2. Patel MV, Deshpande PK, Bhawsar SB, Bhagwat SS, Jafri MA, Mishra A, Pavase L, Gupta S, Kale R, Joshi SN (2011) 1,6-diaza- bicyclo[3.2.1]octane-7-one derivatives and their use in treatment of bacterial infections. World Intellectual Property Organization: International application published under the patent cooperation treaty (PCT), Publication Number US2014/0148431A1

  3. Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK (2017) WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother 61(5):e00072-17. https://doi.org/10.1128/AAC.00072-17

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M (2017) WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother 72(6):1696–1703. https://doi.org/10.1093/jac/dkx050

    Article  CAS  PubMed  Google Scholar 

  5. Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N (2017) In vitro activity of cefepime/zidebactam (WCK 5222) against gramnegative bacteria. J Antimicrob Chemother 56(5):1373–1385. https://doi.org/10.1093/jac/dkw593

    Article  CAS  Google Scholar 

  6. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonoma RA, Oliver A (2017) WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent “β-lactam enhancer” activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-β-lactamase-producing high-risk clones. Antimicrob Agents Chemother 61(6):e02529-16. https://doi.org/10.1128/AAC.02529-16

    Article  PubMed  PubMed Central  Google Scholar 

  7. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonoma RA, Oliver A (2017) Potent β-lactam enhancer activity of zidebactam and WCK 5153 against Acinebacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother 61(11):e01238-17. https://doi.org/10.1128/AAC.01238-17

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rawat T, Pandey IP (2015) Forced degradation studies for drug substance and drug products—scientific and regulatory considerations. J Pharm Sci Res 7(5):238–241

    CAS  Google Scholar 

  9. ICH (2002) M4Q (R1) International conference on harmonisation tripartite guideline. The common technical document for the registration of pharmaceuticals for human use: quality. http://www.ich.org

  10. ICH (2006) Q3A (R2) Impurities in new drug substance. In: International conference on harmonisation tripartite guideline. The common technical document for the registration of pharmaceuticals for human use. http://www.ich.org

  11. ICH (1999) Q6A specifications: Test procedures and acceptance, criteria for new drug substances and new drug products: chemical substances. In: International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org

  12. Patil KR, Tambe H, Zope V, Chavan RP, Yeole RD, Patel MV (2018) Simultaneous determination of zidebactam and cefepime in dog plasma by LC–MS.MS and its application to pre-clinical pharmacokinetic study. Biomed Chromatog 32(8):e4249. https://doi.org/10.1002/bmc.4249

    Article  CAS  Google Scholar 

  13. Suryawanshi G, Bandal R, Harole M, Pise K (2016) A validated stability indicating RP-HPLC method for simultaneous determination of avibactam and ceftazidime in bulk and pharmaceutical dosage form. World J Pharmacy Pharm Sci 5(7):1611–1621

    CAS  Google Scholar 

  14. Shaikh MN, Sadath A (2015) RP-HPLC method development and validation for the simultaneous estimation of ceftazidime and avibactam in intravenous infusion. Int J Eng Tech Sci 2(11):1–5

    Google Scholar 

  15. Sillen H, Mitchell R, Sleigh R, Mainwaring G, Catton K, Houghton R, Glending K (2015) Determination of avibactam and ceftazidime in human plasma samples by LC–MS. Bioanal 7(12):1423–1434

    Article  CAS  Google Scholar 

  16. Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Sheng Bi, Cynthia M, Eng C, Zhang Z, Butterton JR (2018) Intrapulmonary pharmacokinetics of relebactam, a novel β-lactamase inhibitor, dosed in combination with imipenem/cilastatin in healthy subjects. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01411-17

    Article  PubMed  PubMed Central  Google Scholar 

  17. ICH (2005) Q2R1 Validation of analytical procedure text and methodology. In: International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org

  18. ICH (1996) Q1B Stability testing: photo-stability testing of new drug substances and products. In: International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org

  19. http://www.ymc.co.jp/en/columns/hydrosphere_c18/index.html. Accessed 2011

Download references

Acknowledgements

Authors thank the management of Wockhardt Limited for supporting this work.

Funding

This study is part of Wockhardt Ltd in house drug discovery programe.

Author information

Authors and Affiliations

  1. Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India

    Vipul P. Rane, Vinod K. Ahirrao, Kiran R. Patil, Rajiv A. Jadhav & Ravindra D. Yeole

Authors
  1. Vipul P. Rane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinod K. Ahirrao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiran R. Patil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rajiv A. Jadhav
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ravindra D. Yeole
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vipul P. Rane.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest regarding publication of this manuscript.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 42 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rane, V.P., Ahirrao, V.K., Patil, K.R. et al. Impurity Profiling of a Novel β-Lactam Enhancer: Zidebactam. Chromatographia 83, 423–437 (2020). https://doi.org/10.1007/s10337-019-03845-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-019-03845-3

Keywords

Search

Navigation